Treatment News : First Test of New Cancer Drug in People With HIV Is Promising

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » June 2011

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

June 6, 2011

First Test of New Cancer Drug in People With HIV Is Promising

A newer cancer drug, Sutent (sunitinib), is tolerable when paired with at least some antiretroviral (ARV) drugs in people with HIV. The study results, presented at the 2011 meeting of the American Society of Clinical Oncology, being held June 3 to 7 in Chicago, represent an important step forward, as many cancer drugs are not tested in people with HIV.

Though rates of non-HIV-related cancers are on the rise in HIV-positive people, the science isn’t keeping up with this new threat. Health care providers and their HIV-positive patients who have cancer must frequently make an extremely difficult decision—stick with known, but older and less effective cancer treatments, or risk serious side effects and drug interactions with newer treatments that have never been tested in people with HIV. This is because all studies of new cancer drugs currently exclude people with HIV from their trials, and the makers of those new drugs don’t generally sponsor HIV studies at later time points.

In an effort to begin addressing this problem, John Deeken, MD, from the Georgetown Lombardi Comprehensive Cancer Center in Washington, DC, and his colleagues, designed a study of Sutent—which is approved to treat kidney and gastrointestinal cancer and which has the potential for serious drug interactions with some ARV drugs.

Deeken’s group treated 19 people with HIV and cancer between 2008 and 2011. All of the people were on a stable ARV regimen and completed at least one cycle of Sutent therapy at 50 milligrams per day. Sutent requires the same liver enzyme, CYP3A4, to be broken down and eliminated from the body as a number of HIV drugs—notably Norvir (ritonavir). Some of the study participants were taking ARV regimens including Norvir, and some were not.

Deeken and his team found that people on regimens without Norvir did just as well on Sutent as HIV-negative cancer patients. They were no more likely to have side effects or more severe side effects. This group also had no ill effects on their immune systems. The group taking Norvir, however, did have additional side effects from Sutent, including neutropenia, which is a loss of white blood cells and which can be more of a problem in people with HIV.

The trial is not yet complete. This first round of data was focused on how or whether Sutent could be paired with ARV drugs. Longer-term safety and guidance on Sutent dose changes will be reported when the study is finished.

“Our HIV disease is now frequently being well controlled with HAART medications, but we are still having multiple medical problems including getting cancer earlier and more frequently,” said James Weihe, an HIV-positive community representative for the AIDS Malignancy Consortium, one of the trial sponsors. “I am 60 years old and have been diagnosed with three minor cancers and two major cancers within the last two years.

“Dr. Deeken and the work his colleagues are doing give us new hope,” Weihe continues. “Their research shows that we can be included in cancer research trials if the dosages of the medications are adjusted to avoid drug-drug interactions and other side effects.”

Search: Sutent, sunitinib, John Deeken, Georgetown Lombardi Comprehensive Cancer Center, Washington, cancer, chemotherapy, kidney cancer, gaastrointestinal cancer, malignancy, AIDS Malignancy Consortium, James Weihe, CYP3A4, Norvir, ritonavir, neutropenia, American Society of Clinical Oncology


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    Hillcrester
    Ramona
    California


    Sloan1
    Dallas
    Texas


    cortaza100
    Oakland
    California


    Fergie911
    Chicago
    Illinois
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Are you a regular coffee drinker?

Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.